Immunologic Research

, Volume 34, Issue 1, pp 67–87

Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression

  • Ralf-Holger Voss
  • Jürgen Kuball
  • Renate Engel
  • Philipe Guillaume
  • Pedro Romero
  • Christoph Huber
  • Matthias Theobald
Article

DOI: 10.1385/IR:34:1:67

Cite this article as:
Voss, RH., Kuball, J., Engel, R. et al. Immunol Res (2006) 34: 67. doi:10.1385/IR:34:1:67

Abstract

Retroviral transfer of T cell antigen receptor (TCR) genes selected by circumventing tolerance to broad tumor- and leukemia-associated antigens in human leukocyte antigen (HLA)-A*0201 (A2.1) transgenic (Tg) mice allows the therapeutic reprogramming of human T lymphocytes. Using a human CD8×A2.1/Kb mouse-derived TCR specific for natural peptide-A2.1 (pA2.1) complexes comprising residues 81–88 of the human homolog of the murine double-minute 2 oncoprotein, MDM2(81–88), we found that the heterodimeric CD8αβ coreceptor, but not normally expressed homodimeric CD8αα, is required for tetramer binding and functional redirection of TCR-transduced human T cells. CD8+T cells that received a humanized derivative of the MDM2 TCR bound pA2.1 tetramers only in the presence of an anti-human-CD8 antibody and required more peptide than wild-type (WT) MDM2 TCR+ T cells to mount equivalent cytotoxicity. They were, however, sufficiently effective in recognizing malignant targets including fresh leukemia cells. Most efficient expression of transduced TCR in human T lymphocytes was governed by mouse as compared to human constant (C) αβ domains, as demonstrated with partially humanized and murinized TCR of primary mouse and human origin, respectively. We further observed a reciprocal relationship between the level of Tg WT mouse relative to natural human TCR expresion, resulting in T cells with decreased normal human cell surface TCR. In contrast, natural human TCR display remained unaffected after delivery of the humanized MDM2 TCR. These results provide important insights into the molecular basis of TCR gene therapy of malignant disease.

Key Words

MDM2T cellT cell antigen receptorTumor immunityCD8αβ

Copyright information

© Humana Press Inc 2006

Authors and Affiliations

  • Ralf-Holger Voss
    • 4
  • Jürgen Kuball
    • 4
  • Renate Engel
    • 4
  • Philipe Guillaume
    • 1
  • Pedro Romero
    • 2
  • Christoph Huber
    • 4
  • Matthias Theobald
    • 4
  1. 1.Ludwig Institute for Cancer ResearchLausanne BranchEpalingesSwitzerland
  2. 2.Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne BranchHôpital OrthopédiqueLausanneSwitzerland
  3. 3.Fred Hutchinson Cancer Research CenterSeattle
  4. 4.Department of Hematology and OncologyJohannes Gutenberg-UniversityMainzGermany